(Q38193826)

English

Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy

scientific article published on January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy (English)

1 reference

Europe PubMed Central

30 August 2017

0 references

1 reference

based on heuristic

inferred from title

diabetic retinopathy

1 reference

based on heuristic

inferred from title

proliferative diabetic retinopathy

1 reference

based on heuristic

inferred from title

author name string

J Fernando Arevalo

1

1 reference

Europe PubMed Central

30 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2013

1 reference

Europe PubMed Central

30 August 2017

Medical Hypothesis, Discovery & Innovation ophthalmology journal

1 reference

Europe PubMed Central

30 August 2017

2

1 reference

Europe PubMed Central

30 August 2017

1

1 reference

Europe PubMed Central

30 August 2017

20-24

1 reference

Europe PubMed Central

30 August 2017

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Intravitreal bevacizumab for diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Ranibizumab treatment of patients with ocular diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

The role of growth factors in the pathogenesis of diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Single versus Multiple Treatment Sessions of Argon Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Macular edema following panretinal photocoagulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

6 September 2017

Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

23 June 2018

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939761

31 August 2018

Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegaptanib sodium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13

1 reference

https://pubmed.ncbi.nlm.nih.gov/24600636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38193826&oldid=1641212483"